Previous large-scale genomic studies have collectively identified essential genomic alterations that were frequently dysregulated in GBM, including somatic mutations and/or copy number alterations in EGFR, PTEN, TP53, CDKN2A, etc. [11, 26–28]. The gene discussed is CDKN2A; the disease is glioblastoma.